Cisapride (R 51619): A Benchmark 5-HT4 Agonist & hERG Inhibitor for Cardiac Electrophysiology

Executive Summary: Cisapride (R 51619), provided by APExBIO, is a nonselective 5-HT4 receptor agonist and a potent inhibitor of the hERG potassium channel, making it a gold-standard tool in cardiac electrophysiology research (APExBIO product page). Its chemical identity is 4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-methoxybenzamide, with a molecular weight of 465.95 g/mol. It is highly soluble in DMSO (≥23.3 mg/mL at 25°C), moderately soluble in ethanol (≥3.47 mg/mL), and insoluble in water. Cisapride is integral for in vitro studies of 5-HT4-mediated signaling and hERG channel inhibition, especially in iPSC-derived cardiomyocyte models for cardiotoxicity screening (Grafton et al. 2021). Recent advances include deep-learning-enabled phenotypic screening, linking compound exposure to arrhythmogenic risk in human cells. Proper storage at -20°C ensures chemical stability; B1198 is supplied with 99.7% purity and full quality control documentation.

Biological Rationale

Cisapride (R 51619) is structurally designed to target serotonergic and cardiac ion channel pathways. As a nonselective 5-HT4 receptor agonist, it modulates gastrointestinal motility and neuronal signaling. Its inhibition of the hERG potassium channel (KCNH2) underpins its historical clinical use and subsequent withdrawal due to arrhythmogenic liability (Grafton et al. 2021). The hERG channel is central to cardiac repolarization; its blockade prolongs the QT interval, elevating risk for torsades de pointes. In research, Cisapride enables controlled interrogation of 5-HT4 signaling and hERG-mediated cardiac electrophysiology. The compound is also a reference standard in high-throughput predictive cardiotoxicity assays using human iPSC-derived cardiomyocytes—models that better recapitulate human cardiac biology than immortalized cell lines.

Mechanism of Action of Cisapride (R 51619)

• Cisapride acts as a nonselective agonist at 5-HT4 receptors, stimulating cyclic AMP production in gut and neuronal tissues (EC₅₀ ≈ 4–20 nM, depending on tissue type and assay conditions; see APExBIO).
• It blocks the hERG (KCNH2) potassium channel with high potency (IC₅₀ ≈ 10–30 nM in mammalian cell patch-clamp assays at physiological temperature and pH), leading to prolonged cardiac action potential duration.
• Both actions are concentration-dependent and observable in heterologous expression systems (e.g., HEK293 cells) as well as primary or iPSC-derived cardiomyocyte models.
• The dual pharmacology underlies its utility in dissecting proarrhythmic mechanisms and serotonin-mediated gastrointestinal signaling.

Evidence & Benchmarks

• Cisapride exposure (≥10 nM, 24 h, 37°C) in human iPSC-derived cardiomyocytes reliably induces measurable arrhythmogenic phenotypes, including action potential prolongation and early afterdepolarizations (Grafton et al. 2021, https://doi.org/10.7554/eLife.68714).
• In high-content screening, deep learning algorithms detect Cisapride-induced cardiotoxicity signatures at concentrations as low as 30 nM, outperforming manual scoring systems (Grafton et al. 2021, https://doi.org/10.7554/eLife.68714).
• Cisapride displays an IC₅₀ for hERG block in the range of 10–30 nM in patch-clamp studies at 37°C, pH 7.4 (APExBIO, product page).
• Solubility is ≥23.3 mg/mL in DMSO and ≥3.47 mg/mL in ethanol at 25°C, but negligible in water (<1 mg/mL), impacting assay formulation (APExBIO, product page).
• Storage at -20°C preserves compound integrity for >12 months in solid form; solutions are not recommended for long-term storage due to potential hydrolysis (APExBIO, product page).

See also: Cisapride (R 51619): Catalyzing Predictive Cardiotoxicity—this article updates and extends the discussion by focusing on machine learning-based phenotypic screening benchmarks and stability parameters.

Applications, Limits & Misconceptions

Cisapride is a validated reference for in vitro cardiotoxicity and proarrhythmia models, especially in hERG safety pharmacology. It also serves as a probe for gastrointestinal motility studies via 5-HT4 pathway activation. In translational workflows, it enables benchmark comparisons for new chemical entities (NCEs) in high-throughput screening. Recent studies leverage iPSC-derived cardiomyocytes and deep-learning image analysis to detect subtle toxic effects—improving detection sensitivity and reducing late-stage drug attrition (Grafton et al. 2021).

Common Pitfalls or Misconceptions

• Misconception: Cisapride is suitable for long-term solution storage. Fact: Only solid-form storage at -20°C is recommended; solutions degrade rapidly.
• Misconception: Cisapride is selective for 5-HT4 receptors. Fact: It is nonselective and also potently inhibits hERG channels.
• Misconception: Cisapride is soluble in water. Fact: It is essentially insoluble in water (<1 mg/mL at 25°C).
• Misconception: hERG inhibition by Cisapride is only relevant at high concentrations. Fact: Significant hERG block and arrhythmogenic risk are observed at nanomolar levels.
• Misconception: All cells respond identically to Cisapride. Fact: Sensitivity varies depending on species, cell type, and experimental model.

For a broader discussion on next-generation in vitro models using Cisapride, see Cisapride (R 51619): Next-Gen Models for Cardiac and GI Studies. This article clarifies recent developments in phenotypic screening and deep learning not covered in earlier reviews.

Workflow Integration & Parameters

• Preparation: Dissolve Cisapride in DMSO (≥23.3 mg/mL at 25°C) or ethanol (≥3.47 mg/mL); vortex until fully dissolved. Avoid water-based buffers for stock solutions.
• Storage: Store solid at -20°C. Prepare aliquots to minimize freeze/thaw cycles. Use fresh solutions for each experiment.
• Concentration Range: Typical effective concentrations for hERG and 5-HT4 studies: 1–1000 nM; optimize based on cell type and assay sensitivity.
• Quality Control: APExBIO supplies Cisapride B1198 at ≥99.7% purity, validated by HPLC, NMR, and MSDS documentation (APExBIO).
• Model Integration: For predictive cardiotoxicity, use iPSC-derived cardiomyocytes and incorporate high-content imaging with deep-learning analytics, as benchmarked in recent eLife studies (Grafton et al. 2021).

For comparison of mechanistic insights and translational applications, see Cisapride (R 51619): Advancing Predictive Cardiac Electrophysiology, which addresses regulatory and competitive aspects not detailed here.

Conclusion & Outlook

Cisapride (R 51619) remains a cornerstone reference for dissecting 5-HT4 receptor signaling and hERG-related cardiotoxicity in preclinical research. Its role as a standard in deep-learning-enabled, iPSC-based phenotypic assays ensures robust detection of arrhythmogenic liabilities. APExBIO’s B1198 kit offers high-purity, quality-controlled material suitable for demanding workflows. Ongoing innovation in human cell models and AI-driven analytics will further enhance the predictive power of Cisapride-based assays, supporting safer, more effective drug discovery pipelines.